345 results on '"Giacomini, Patrizio"'
Search Results
2. Surface plasmon resonance biosensor with anti-crossing modulation readout
3. The Molecular Tumor Board of the Regina Elena National Cancer Institute: from accrual to treatment in real-world
4. Direct competitive assay for HER2 detection in human plasma using Bloch surface wave-based biosensors
5. A highly sensitive electrochemical magneto-genosensing assay for the specific detection of a single nucleotide variation in the KRAS oncogene in human plasma
6. Widespread in vivo efficacy of The-0504: A conditionally-activatable nanoferritin for tumor-agnostic targeting of CD71-expressing cancers
7. Bridging therapeutic opportunities: a survey by the Italian molecular tumor board workgroup of Alliance Against Cancer
8. Molecular Tumor Boards: on the evolution of species
9. Surface Plasmon Resonance Biosensor with Anti-Crossing Modulation Readout
10. Liquid biopsy identifies actionable dynamic predictors of resistance to Trastuzumab Emtansine (T-DM1) in advanced HER2-positive breast cancer
11. High activity and low toxicity of a novel CD71-targeting nanotherapeutic named The-0504 on preclinical models of several human aggressive tumors
12. Detection of soluble ERBB2 in breast cancer cell lysates using a combined label-free/fluorescence platform based on Bloch surface waves
13. Cross-sectional analysis of circulating tumor DNA in primary colorectal cancer at surgery and during post-surgery follow-up by liquid biopsy
14. Selective delivery of doxorubicin by novel stimuli-sensitive nano-ferritins overcomes tumor refractoriness
15. Data from Natural Killer Cells Efficiently Reject Lymphoma Silenced for the Endoplasmic Reticulum Aminopeptidase Associated with Antigen Processing
16. Supplementary Methods, Figure Legends 1-6 from NF-κB, and not MYCN, Regulates MHC Class I and Endoplasmic Reticulum Aminopeptidases in Human Neuroblastoma Cells
17. Supplementary Figure 3 from NF-κB, and not MYCN, Regulates MHC Class I and Endoplasmic Reticulum Aminopeptidases in Human Neuroblastoma Cells
18. Supplementary Figure 5 from Natural Killer Cells Efficiently Reject Lymphoma Silenced for the Endoplasmic Reticulum Aminopeptidase Associated with Antigen Processing
19. Supplementary Figure 2 from NF-κB, and not MYCN, Regulates MHC Class I and Endoplasmic Reticulum Aminopeptidases in Human Neuroblastoma Cells
20. Supplementary Figure 6 from NF-κB, and not MYCN, Regulates MHC Class I and Endoplasmic Reticulum Aminopeptidases in Human Neuroblastoma Cells
21. Supplementary Figure 4 from NF-κB, and not MYCN, Regulates MHC Class I and Endoplasmic Reticulum Aminopeptidases in Human Neuroblastoma Cells
22. Supplementary Figure 1 from Natural Killer Cells Efficiently Reject Lymphoma Silenced for the Endoplasmic Reticulum Aminopeptidase Associated with Antigen Processing
23. Supplementary Table 1 from Natural Killer Cells Efficiently Reject Lymphoma Silenced for the Endoplasmic Reticulum Aminopeptidase Associated with Antigen Processing
24. Supplementary Figure 5 from NF-κB, and not MYCN, Regulates MHC Class I and Endoplasmic Reticulum Aminopeptidases in Human Neuroblastoma Cells
25. Supplementary Figure 3 from Natural Killer Cells Efficiently Reject Lymphoma Silenced for the Endoplasmic Reticulum Aminopeptidase Associated with Antigen Processing
26. Supplementary Methods, Legends for Figures 1-5 from Natural Killer Cells Efficiently Reject Lymphoma Silenced for the Endoplasmic Reticulum Aminopeptidase Associated with Antigen Processing
27. Supplementary Figure 2 from Natural Killer Cells Efficiently Reject Lymphoma Silenced for the Endoplasmic Reticulum Aminopeptidase Associated with Antigen Processing
28. Supplementary Figure 1 from NF-κB, and not MYCN, Regulates MHC Class I and Endoplasmic Reticulum Aminopeptidases in Human Neuroblastoma Cells
29. Supplementary Figure 4 from Natural Killer Cells Efficiently Reject Lymphoma Silenced for the Endoplasmic Reticulum Aminopeptidase Associated with Antigen Processing
30. Abstract OT1-22-01: Liquid biopsy and Ado-trastuzumab emtansine (T-DM1): drug-resistance traits in the blood of HER2-positive metastatic breast cancer patients
31. Metastatic Melanoma: Liquid Biopsy as a New Precision Medicine Approach
32. Unusual phylogenetic tree and circulating actionable ESR1 mutations in an aggressive luminal/HER2-low breast cancer: Case report
33. Direct competitive assay for ERBB2 detection in breast cancer cell lysates using 1D photonic crystals-based biochips
34. Optical multiplexed bioassays on photonic crystals for breast cancer biomarker detection
35. End9: an early-passage cell line defective in master HLA-I transcriptional coordinators
36. Liquid biopsy in mice bearing colorectal carcinoma xenografts: gateways regulating the levels of circulating tumor DNA (ctDNA) and miRNA (ctmiRNA)
37. Tearing down the walls: FDA approves next generation sequencing (NGS) assays for actionable cancer genomic aberrations
38. Dynamic circulating tumor DNA (ctDNA) in monitoring trastuzumab deruxtecan (TDXd) activity for patients (pts) with advanced breast cancer: Preliminary results of a feasibility study.
39. Additional file 1 of Bridging therapeutic opportunities: a survey by the Italian molecular tumor board workgroup of Alliance Against Cancer
40. Melanoma molecular classes and prognosis in the postgenomic era
41. Multiplexed bio-assay for a reliable detection of HER2 in human plasma using a combined label-free/fluorescence biosensing platform
42. Molecular Immunoevasion Strategies Targeting Antigen Processing and Presentation
43. Two distinct TP53 mutations in HNSCC primary tumor: Only one circulates in the blood
44. TOOLBOX: Strep-Tagged nano-assemblies of antibody-drug-conjugates (ADC) for modular and conditional cancer drugging
45. Additional file 1 of High activity and low toxicity of a novel CD71-targeting nanotherapeutic named The-0504 on preclinical models of several human aggressive tumors
46. [Corrigendum] TOOLBOX: Strep‑Tagged nano‑assemblies of antibody‑drug‑conjugates (ADC) for modular and conditional cancer drugging
47. Detection of Tumor DNA in Human Plasma with a Functional PLL-Based Surface Layer and Plasmonic Biosensing
48. Precision Medicine and Melanoma: Multi-Omics Approaches to Monitoring the Immunotherapy Response
49. A melanoma immune response signature including Human Leukocyte Antigen-E
50. Additional file 4 of Cross-sectional analysis of circulating tumor DNA in primary colorectal cancer at surgery and during post-surgery follow-up by liquid biopsy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.